The short answer
Ginkgo should be reviewed before use with dabigatran etexilate. Bleeding is a plausible concern and NIH cautions about use with anticoagulants, but studies involving warfarin do not prove an interaction with dabigatran. There is no established spacing schedule that makes this combination safe.
What this answer covers
Oral Ginkgo biloba products with adult oral dabigatran etexilate; leaf extracts are distinguished from seeds, other plant parts and mixed products.
- Supplement or preparation
- Ginkgo
- Medication ingredient
- dabigatran etexilate
What do the available studies show?
A small crossover study in 24 warfarin-treated outpatients found stable INR with ginkgo 100 mg daily over four-week periods. A much larger observational analysis of warfarin users found an association between ginkgo co-use and bleeding. Different designs, product documentation and confounding help explain why these findings are not interchangeable.
Why does that not settle this combination?
Dabigatran etexilate is the swallowed prodrug. The body converts it to dabigatran, which directly inhibits thrombin. Neither warfarin study measured the effect of ginkgo on dabigatran exposure or its clinical bleeding outcomes. INR observations in warfarin users cannot establish compatibility with a different anticoagulant. The observational association is a warning signal, not a pair-specific estimate for this medicine.
Which details should I check?
Many supplements contain leaf extracts, but product strength and additional ingredients vary. A seed product or mixture should not be treated as the extract used in a study. Review aspirin, anti-inflammatory pain medicines and other supplements at the same time, because the combined medication list can change bleeding risk.
Is changing the time of day enough?
No reliable study establishes an effective gap between ginkgo and dabigatran etexilate, and there is no evidence that this anticoagulant creates a need for ginkgo. Discuss whether the supplement is worthwhile before starting or increasing it. Report unusual bleeding promptly and obtain urgent care for severe symptoms; do not skip prescribed anticoagulation to make room for ginkgo.
Evidence and practical considerations
Side effects & toxicity
Ginkgo should be reviewed before use with dabigatran etexilate. Bleeding is a plausible concern and NIH cautions about use with anticoagulants, but studies involving warfarin do not prove an interaction with dabigatran. There is no established spacing schedule that makes this combination safe.
- Exact scope
- Oral Ginkgo biloba products with adult oral dabigatran etexilate; leaf extracts are distinguished from seeds, other plant parts and mixed products. with adult oral dabigatran etexilate mesylate capsules; active dabigatran produced after absorption
- Medication form and route
- adult oral dabigatran etexilate mesylate capsules; active dabigatran produced after absorption
- Timing or duration
- Concurrent oral use. Source-specific durations are recorded in the evidence entries; no unstudied duration threshold or separation schedule is inferred.
What remains uncertain
- Indirect warfarin evidence and general NIH guidance; no direct controlled pair study located. Leaf/seed distinctions and commercial variability limit extrapolation. Timing and increased supplement need are unestablished.
Factors that may matter: Exact supplement preparation, dose and additional ingredients; Kidney function, age, bleeding history and other antiplatelet or anticoagulant medicines; Current medication formulation and recent supplement start or stop.
Read the supporting source summaries
Source 1: current U.S. regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients receiving oral dabigatran etexilate capsules.
P-gp induction reduces active dabigatran exposure. P-gp inhibition and impaired renal function increase exposure. Capsules must be swallowed intact. RE-LY trough concentrations were not appreciably changed by concomitant PPIs or H2 blockers.
How this applies: Establishes the exact medicine’s mechanism, baseline bleeding precautions and formulation/transport limitations; it does not establish this supplement-specific interaction. Exact scope: Oral Ginkgo biloba products with adult oral dabigatran etexilate; leaf extracts are distinguished from seeds, other plant parts and mixed products.
Named medicine dose adjustments cannot be extrapolated to untested herbs. Label silence about a supplement does not prove compatibility. Capsule results must not be generalized to every formulation.
Source 2: government botanical safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: People considering ginkgo supplements, including those taking anticoagulants.
NIH cautions about bleeding risk with anticoagulants and advises discussing supplement use with a clinician.
How this applies: It is interpreted only alongside the current dabigatran etexilate label; any source using warfarin or no anticoagulant is indirect for this pair. Exact scope: Oral Ginkgo biloba products with adult oral dabigatran etexilate; leaf extracts are distinguished from seeds, other plant parts and mixed products.
General safety guidance, not a controlled apixaban or dabigatran interaction study, and not an estimate for every preparation.
Source 3: peer-reviewed original research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 24 outpatients on stable long-term warfarin; three withdrew.
INR remained stable and mean weekly warfarin dose did not differ significantly across periods.
How this applies: Applied only as indirect context; the study or guidance did not establish an interaction with this exact direct oral anticoagulant. It is interpreted only alongside the current dabigatran etexilate label; any source using warfarin or no anticoagulant is indirect for this pair. Exact scope: Oral Ginkgo biloba products with adult oral dabigatran etexilate; leaf extracts are distinguished from seeds, other plant parts and mixed products.
Small short crossover with adjusted warfarin doses; cannot exclude rare events, different products or larger doses.
Source 4: peer-reviewed original research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Large Veterans Administration electronic-record cohort of warfarin users.
Adjusted analysis associated ginkgo co-use with bleeding events, hazard ratio 1.38 (95% confidence interval 1.20 to 1.58).
How this applies: Applied only as indirect context; the study or guidance did not establish an interaction with this exact direct oral anticoagulant. It is interpreted only alongside the current dabigatran etexilate label; any source using warfarin or no anticoagulant is indirect for this pair. Exact scope: Oral Ginkgo biloba products with adult oral dabigatran etexilate; leaf extracts are distinguished from seeds, other plant parts and mixed products.
Observational signal with uncertain supplement adherence, dose and timing; residual confounding and record-extraction error remain possible.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Current labels and targeted original sources assessed; all current available claims adjudicated and consumer article prepared. Uncertainty and indirect evidence retained. Clinical sign-off not recorded. | |
| Research summary published |
Article revision: 78ab8b2db9a1859d
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.